Company Overview - Tongling Jeya Biotechnology Co., Ltd. was established in 1999, specializing in the research, production, and sales of wet wipes, with over 20 years of industry experience [2]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on December 3, 2021, and is steadily advancing its fundraising projects [2]. Financial Performance - In Q1 2025, the company reported a revenue of 124 million yuan and a net profit of 10.06 million yuan [2]. Business Operations - As of Q2 2025, the company has a stable order flow in its wet wipes business, with existing customers in Europe and Canada [3]. - The current production capacity utilization rate is approximately 80% [3]. - The U.S. wet wipes factory is under construction and is expected to commence production next year, primarily serving international brand clients in the North American market [3]. Clientele and Market Expansion - Key clients in the wet wipes business include international brands such as Woolworths, Kimberly-Clark, Johnson & Johnson, Procter & Gamble, as well as domestic e-commerce brands like Babycare and Dongfang Zhenxuan [3]. - The company anticipates that overseas orders will increase, with foreign sales expected to account for over 50% of total business in 2025 [3]. Risk Management - Investment risks associated with the U.S. factory include uncertainties in facility renovation and approval processes, customer audit outcomes, potential delays in production timelines, and cultural differences affecting production efficiency [3]. Future Business Strategy - The company plans to expand its cosmetics business, primarily through contract manufacturing for L'Oréal, while also exploring domestic clients [4]. - The current revenue from proprietary brands is low, with a focus on contract manufacturing [4]. - Future business drivers include expanding existing brand client relationships and leveraging the new U.S. factory [4]. Stock Performance - The company's stock price fluctuations are influenced by macroeconomic factors, industry policies, and market sentiment, with no undisclosed significant information affecting operations as of the date of the meeting [4].

Summary of Key Points from the Conference Call of Jieya Co., Ltd. Company Overview - Jieya Co., Ltd. is benefiting from Kimberly-Clark's strategic adjustments in the European market, with expected new orders in 2025 bringing nearly 200 million RMB in sales [2][6] - The company is actively expanding its business in Australia, New Zealand, Southeast Asia, and Latin America, indicating significant growth in international markets [2] Core Business Developments - Jieya has secured a project with Procter & Gamble in the Canadian market, with an expected annual sales of approximately 30 million RMB, potentially increasing to nearly 100 million RMB [2][8] - The new factory in North Carolina, USA, originally planned to start production in 2025, has been delayed to Q1 2026 due to approval and client review factors, with a designed capacity of 100 million USD [2][11] - In the first half of 2025, Jieya's revenue growth is expected to be around 10%, with better profit growth anticipated, and a faster growth rate expected in the second half of the year [2][15] Client and Market Structure - Jieya primarily serves major international brands such as Johnson & Johnson, Kimberly-Clark, Procter & Gamble, L'Oréal, and Australia's largest supermarket chain, Woolworths [4] - The company's business structure is heavily focused on wet wipes, which constitute the majority of its offerings, while cosmetics account for about 10% of overall business [4] Financial Performance and Projections - In Q1 2025, Jieya reported a slight decline in performance, but a recovery is expected in Q2 due to new orders, with overall performance showing improvement [3][15] - The company has a strong financial reserve of approximately 1.3 billion RMB, sufficient to support business expansion [5][30] Strategic Partnerships and Market Trends - The strategic shift by Kimberly-Clark to outsource production has created opportunities for Jieya, with a significant increase in orders expected [7] - The wet wipes industry is facing increased competition from new entrants, but major players like Jieya focus on their market shares without significant conflict [17] Future Growth and Investment Plans - Jieya aims to explore international market opportunities and product categories as key growth drivers, with plans to maintain stable growth in core business areas [13][14] - The company is considering investments and acquisitions to seek business growth, particularly targeting brand collaborations [24] Challenges and Risks - The company faces challenges in the cosmetics sector due to reduced orders from L'Oréal, but it plans to continue serving L'Oréal while expanding domestic client relationships [5][23] - There are uncertainties regarding the production timeline of the new factory in the USA, which could impact future revenue [11][20] Export and Domestic Sales Dynamics - Jieya's export ratio is expected to increase from 50% in 2024 to 70% in 2025, while domestic sales are projected to decrease to 30% [27] Profitability Outlook - The gross margin is projected to improve as international business grows, with current margins around 20%-25% for international operations and about 10% for domestic [28] Conclusion - Jieya Co., Ltd. is positioned for growth through strategic partnerships, international market expansion, and a focus on core competencies in wet wipes, while navigating challenges in the cosmetics sector and maintaining a strong financial foundation [31]

Company Overview - Tongling Jieya Biotechnology Co., Ltd. was established in 1999 and specializes in the research, production, and sales of wet wipes, with over 20 years of industry experience [2]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on December 3, 2021, and is steadily advancing its fundraising projects [2]. - In Q1 2025, the company reported a revenue of 124 million yuan and a net profit of 10.06 million yuan [2]. Q&A Highlights - **Impact of Tariffs**: The current tariff policies have a relatively limited impact on the company's overall business [3]. - **US Wet Wipe Factory Project**: The project is currently under construction and is expected to commence production next year [3]. - **Kimberly-Clark European Orders**: Production began in April 2025, and order deliveries are progressing as planned [3]. - **Asset Impairment**: The company adheres to accounting standards and will reasonably assess asset impairment based on prudence [3]. - **Self-Branding Considerations**: The company is exploring self-branding through an industrial fund but has seen low revenue conversion rates [3]. - **Facial Mask Business Outlook**: Currently serving major clients like L'Oréal and Galen Group, with a gradual expansion to other domestic brands, though new client orders are relatively small [3]. - **Jiechuang Medical Subsidiary**: The subsidiary is undergoing strategic adjustments, with cautious investment based on overall business layout and resource optimization [3]. - **Equity Incentives**: The company is focused on establishing long-term incentive mechanisms and will disclose plans as they develop [3]. - **Compliance with Regulations**: The company conducted the investor communication event in accordance with regulatory guidelines, ensuring no undisclosed significant information leaks occurred [3].

Group 1: Company Performance and Challenges - The sales of baby wet wipes decreased by nearly 20% in 2024, primarily due to intensified industry competition and a decline in birth rates [2][3] - The wet wipes industry is highly market-oriented with numerous manufacturers, leading to a gradual market share concentration towards leading companies [3] - The company faces significant challenges due to increased competition and a complex economic environment since its listing [3] Group 2: Future Growth Strategies - The company aims to drive performance growth through product structure optimization, sales strategy adjustments, and technological innovation [3][4] - Direct exports to the U.S. represent a small proportion of the company's products, limiting the impact of recent tariff policies on overall performance [3] - The company plans to leverage capital market advantages to acquire quality assets that align with its main business, enhancing sustainable profitability [3] Group 3: Investor Relations and Governance - The investor relations activity was conducted in compliance with regulatory guidelines, ensuring no significant undisclosed information was leaked [4] - The management emphasizes a commitment to high-quality development and improving investor returns through enhanced governance and compliance [3][4]

证券代码：605009 证券简称：豪悦护理 公告编号：2025-024 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●被担保人名称：杭州豪悦护理用品股份有限公司（以下简称"公司"）的全资子公司江苏豪悦实业有限 公司（以下简称"江苏豪悦"）。 ●担保事项及金额：公司与中国工商银行股份有限公司沭阳支行（以下简称"工商银行"）续签了《最高 额保证合同》，在保证责任期间内，为江苏豪悦提供5000万元的连带责任保证担保。 ●截至本公告发布日，包括本次续签的5000万元担保在内，公司为子公司、子公司为其他子公司累计提 供担保的总额为2亿元，仍在公司2024年度董事会授权的担保总额度5亿元范围内，无需再次提交董事会 审议批准。 ●本次担保是否有反担保：无 ●对外担保逾期的累计数量：无 杭州豪悦护理用品股份有限公司 关于为子公司提供担保进展的公告 一、担保情况概述 （一）担保情况概述 近日，公司与工商银行续签了《最高额保证合同》，在保证责任期间内，为江苏豪悦提供5000万元的连 带责任保证担保。 （二）本次担保事项履行的决 ...

Group 1 - The company reported a revenue of 2.929 billion yuan for 2024, representing a year-on-year growth of 6.25% [1] - The net profit attributable to shareholders of the listed company was 388 million yuan, showing a year-on-year decline of 11.65% [1] - The company announced a cash dividend of 8.5 yuan (including tax) for every 10 shares to all shareholders [1]